Recently updated European Association for the Study of the Liver (EASL) clinical practice guidelines highlight the importance of nucleos(t)ide analogue (NA) prophylaxis in patients with risk of reactivation.[1] Risk factors include B-cell–depleting agents such as rituximab,[2] T-cell–modulating treatments, several cytokine-targeting regimens, and combination immune-modifying therapies. These recommendations highlight the broad vulnerability of patients exposed to intensive or prolonged immunosuppression.
Journal of Hepatology published a clinical update in Research Highlights on 13 Feb 2026.
The item focuses on Incidence and Risk Stratification of Hepatitis B Reactivation in Patients Receiving Anti-CD38 Monoclonal Antibody Therapy.
Review the original article for the full source wording and details.